Anavex Life Sciences, a leading biopharmaceutical company, has recently released positive findings from
the 48-week open-label extension of their phase 2 study involving blarcamesine,
also known as ANAVEX2-73. The study focused on individuals with Parkinson
disease dementia (PDD), a condition with limited treatment options. 

Despite the challenges posed by the COVID-19 pandemic, the study showed significant
improvements in PDD symptoms among patients who continued treatment with
blarcamesine during the extension period. This is an encouraging development
considering the urgent need for effective therapies for Parkinson disease. 

According to Christopher U. Missling, PhD, the President and CEO of Anavex Life Sciences, the
consistent longitudinal improvement in clinical symptoms observed during the
extension phase highlights the potential of blarcamesine to slow down and
potentially reverse the debilitating effects of Parkinson disease. The study’s
primary and secondary endpoints, including the Movement Disorder
Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and the Clinical
Global Impression-Improvement (CGI-I), consistently showed improvements when
patients resumed treatment. 

The study also revealed positive changes in cognitive function and sleep behavior, further
supporting the potential benefits of blarcamesine for individuals with
Parkinson disease dementia. Notably, blarcamesine did not impair sleep and had
a positive effect on rapid eye movement (REM) sleep behavior disorder. 

It is important to note that the study results should be interpreted cautiously due to the small
sample size and the impact of the COVID-19 pandemic on enrollment. However, the
promising findings provide a strong foundation for future research and potential
advancements in the treatment of Parkinson disease dementia. 

Anavex Life Sciences plans to conduct a 6-month study focusing on Parkinson disease to
further investigate the efficacy of blarcamesine. Anavex remains committed to addressing the unmet needs of patients with
neurodegenerative diseases and continues to explore innovative therapeutic options. 

In conclusion, the findings from the phase 2 extension study of blarcamesine in Parkinson disease
dementia demonstrate its potential as a safe and effective treatment option.
With further research and development, blarcamesine could provide much-needed
relief for individuals living with Parkinson disease dementia and their
caregivers. Anavex Life Sciences is dedicated to advancing the field of
neurology and improving the lives of patients worldwide. Refer to this article, for related information. 

Learn more about Anavex on https://www.bloomberg.com/profile/company/AVXL:US